Administration of resveratrol: What formulation solutions to bioavailability limitations?

被引:505
作者
Amri, A. [1 ,2 ]
Chaumeil, J. C. [1 ]
Sfar, S. [2 ]
Charrueau, C. [1 ]
机构
[1] Univ Paris 05, Pharm Galen Lab, EA4466, Fac Sci Pharmaceut & Biol, F-75006 Paris, France
[2] Univ Monastir, Fac Pharm, Pharm Galen Lab, Monastir, Tunisia
关键词
Resveratrol; Bioavailability; Formulation; Controlled release; Delivery; CANCER CHEMOPREVENTIVE AGENT; KAPPA-B ACTIVATION; TRANS-RESVERATROL; CIS-RESVERATROL; DRUG-DELIVERY; PECTINATE BEADS; CELL UPTAKE; RED WINE; IN-VITRO; ABSORPTION;
D O I
10.1016/j.jconrel.2011.09.083
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Resveratrol (3,5,4'-trihydroxystilbene), a naturally occurring polyphenol, has attracted considerable interest for its beneficial potentials for human health, which include anti-oxidant, anti-inflammatory, cardioprotective and anti-tumor activities. However, the in vivo biological effects of resveratrol appear strongly limited by its low bioavailability, which is a barrier to the development of therapeutic applications. In this context, an increasing number of recent studies have aimed at designing novel resveratrol formulations to overcome its poor solubility, limited stability, high metabolization and weak bioavailability. This review outlines physicochemical and pharmacokinetic limitations to resveratrol bioavailability, describes formulations tested for resveratrol administration, controlled release and targeting, and identifies future opportunities for resveratrol delivery. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:182 / 193
页数:12
相关论文
共 92 条
[1]   Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers [J].
Almeida, Luis ;
Vaz-da-Silva, Manuel ;
Falcao, Amilcar ;
Soares, Eva ;
Costa, Raquel ;
Loureiro, Ana I. ;
Fernandes-Lopes, Carlos ;
Rocha, Jose-Francisco ;
Nunes, Teresa ;
Wright, Lyndon ;
Soares-da-Silva, Patricio .
MOLECULAR NUTRITION & FOOD RESEARCH, 2009, 53 :S7-S15
[2]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[3]  
Andlauer W, 2000, DRUG EXP CLIN RES, V26, P47
[4]  
[Anonymous], RES SIGM PROD
[5]   Cyclodextrin-Based Nanosponges for Delivery of Resveratrol: In Vitro Characterisation, Stability, Cytotoxicity and Permeation Study [J].
Ansari, Khalid A. ;
Vavia, Pradeep R. ;
Trotta, Francesco ;
Cavalli, Roberta .
AAPS PHARMSCITECH, 2011, 12 (01) :279-286
[6]   Inhibition of cancer growth by resveratrol is related to its low bioavailability [J].
Asensi, M ;
Medina, I ;
Ortega, A ;
Carretero, J ;
Baño, MC ;
Obrador, E ;
Estrela, JM .
FREE RADICAL BIOLOGY AND MEDICINE, 2002, 33 (03) :387-398
[7]   Solubilization of resveratrol in micellar solutions of different bile acids [J].
Atanackovic, Milica ;
Posa, Mihalj ;
Heinle, Helmut ;
Gojkovic-Bukarica, Ljiljana ;
Cvejic, Jelena .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2009, 72 (01) :148-154
[8]   Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol [J].
Basly, JP ;
Marre-Fournier, F ;
Le Bail, JC ;
Habrioux, G ;
Chulia, AJ .
LIFE SCIENCES, 2000, 66 (09) :769-777
[9]   Therapeutic potential of resveratrol:: the in vivo evidence [J].
Baur, Joseph A. ;
Sinclair, David A. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (06) :493-506
[10]  
Bertelli A, 1998, DRUG EXP CLIN RES, V24, P133